Cargando…

Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease

Elevated low-density lipoprotein cholesterol (LDL-C) level is associated with an increased risk of atherosclerotic cardiovascular disease. Although high-intensity lipid-lowering therapies with statins and ezetimibe are highly effective for reducing LDL-C levels, over half of high-risk patients do no...

Descripción completa

Detalles Bibliográficos
Autor principal:	Nishikido, Toshiyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887852/ https://www.ncbi.nlm.nih.gov/pubmed/36717882 http://dx.doi.org/10.1186/s12933-023-01752-4

Ejemplares similares

Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease
por: Albosta, Michael S, et al.
Publicado: (2023)

Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
por: Kosmas, Constantine E, et al.
Publicado: (2020)

Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis
por: Desai, Nihar R., et al.
Publicado: (2022)

Inclisiran: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
por: Sinning, David, et al.
Publicado: (2020)

Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis
por: Rogula, Sylwester, et al.
Publicado: (2021)

Correction to: Inclisiran: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
por: Ray, Kausik K, et al.
Publicado: (2022)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023)

Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia
por: Kosmas, Constantine E., et al.
Publicado: (2018)

Inclisiran—A Revolutionary Addition to a Cholesterol-Lowering Therapy
por: Dec, Adrianna, et al.
Publicado: (2023)

Inclisiran: a novel drug for the treatment of dyslipidemia
por: Nadeem, Abdullah, et al.
Publicado: (2023)

Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
por: Wołowiec, Łukasz, et al.
Publicado: (2023)

Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus
por: Rakocevic, Jelena, et al.
Publicado: (2023)

Which patients at risk of cardiovascular disease might benefit the most from inclisiran? Polish experts’ opinion. The compromise between EBM and possibilities in healthcare
por: Banach, Maciej, et al.
Publicado: (2022)

Atherosclerotic Cardiovascular Risk in Japan
por: Nojiri, Shuko, et al.
Publicado: (2017)

Inclisiran: How Widely and When Should We Use It?
por: Pirillo, Angela, et al.
Publicado: (2022)

Nutritional Therapy for Asian Patients at Risk for Atherosclerotic Cardiovascular Disease
por: Lim, Hyunjung, et al.
Publicado: (2019)

Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease
por: Galactionova, Katya, et al.
Publicado: (2022)

Inclisiran adjuvant therapy to statins for the use of hypercholesterolemia: a commentary
por: Vohra, Laiba Imran, et al.
Publicado: (2023)

The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function
por: Di Costanzo, Assunta, et al.
Publicado: (2023)

Inflammation in atherosclerotic cardiovascular disease
por: Shah, Prediman K., et al.
Publicado: (2019)

Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia
por: Ebenezer, Oluwakemi, et al.
Publicado: (2023)

Effectiveness and safety of Inclisiran in hyperlipidemia treatment: An overview of systematic reviews
por: Li, Jiayi, et al.
Publicado: (2023)

New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran
por: Ruscica, Massimiliano, et al.
Publicado: (2021)

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
por: Ray, Kausik K, et al.
Publicado: (2022)

Salusins: Potential Use as a Biomarker for Atherosclerotic Cardiovascular Diseases
por: Sato, Kengo, et al.
Publicado: (2013)

Correction to: Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease
por: Galactionova, Katya, et al.
Publicado: (2022)

Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11
por: Koenig, Wolfgang, et al.
Publicado: (2023)

Novel Biomarkers for Atherosclerotic Disease: Advances in Cardiovascular Risk Assessment
por: Jigoranu, Raul-Alexandru, et al.
Publicado: (2023)

Shared Risk Factors between Dementia and Atherosclerotic Cardiovascular Disease
por: Nordestgaard, Liv Tybjærg, et al.
Publicado: (2022)

Inclisiran: a new generation of lipid-lowering siRNA therapeutic
por: Zhang, Yanzhen, et al.
Publicado: (2023)

Lipid lowering with inclisiran: a real-world single-centre experience
por: Padam, Pritpal, et al.
Publicado: (2022)

Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction
por: Nurmohamed, Nick S, et al.
Publicado: (2023)

Fibrinogen and Atherosclerotic Cardiovascular Diseases—Review of the Literature and Clinical Studies
por: Surma, Stanisław, et al.
Publicado: (2021)

Androgen therapy and atherosclerotic cardiovascular disease
por: McGrath, K-CY, et al.
Publicado: (2008)

Atherosclerotic Cardiovascular Disease Beginning in Childhood
por: Hong, Young Mi
Publicado: (2010)

Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials
por: Cupido, Arjen J, et al.
Publicado: (2020)

The Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) Perspectives on the Usage of Inclisiran
por: Elserafy, Ahmed Shawky, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease as an Emerging Risk Factor and Potential Intervention Target for Atherosclerotic Cardiovascular Diseases
por: Zhang, Daqing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4uop4pgn78pnrefovido98ptdh